Please assess the completion status of the following clinical trial:

Trial Title: Study of Revlimid With Doxil and Avastin for Patients With Platinum Resistant Ovarian Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* EOC patients must be platinum resistant/refractory (see 1.1 for definition) and be considered by the attending physician capable of being treated in this study according to GCP.~* Measurable disease by RECIST criteria or evaluable disease by GCIC criteria~* No prior anthracycline or lenalidomide use, unless the dose received was equal or less than one cycle and the patient did not progress on treatment.~* Subjects must have calculated creatinine clearance \> 60ml/min by Cockcroft-Gault formula during the escalation phase.~* Subjects must have calculated creatinine clearance ≥ 30ml/min by Cockcroft-Gault formula during the expansion phase. See section below, Dosing Regimen, regarding lenalidomide dose adjustment for calculated creatinine clearance \> 30ml/min and \< 60ml/min.~* Understand and voluntarily sign an informed consent form.~* All study participants must be registered into the mandatory RevAssist® program, and be willing and able to comply with the requirements of RevAssist®.~* Females of childbearing potential (FCBP)† must have a negative serum or urine pregnancy test with a sensitivity of at least 50 mIU/mL within 10 - 14 days prior to and again within 24 hours of prescribing lenalidomide (prescriptions must be filled within 7 days) and must either commit to continued abstinence from heterosexual intercourse or begin TWO acceptable methods of birth control.~* No contraindication to anticoagulation~Exclusion Criteria:~* Pregnant or breast feeding females. (Lactating females must agree not to breast feed while taking lenalidomide).~* Concurrent use of other anti-cancer agents or treatments.~* Known seropositive for or active viral infection with human immunodeficiency virus (HIV), hepatitis B virus (HBV) or hepatitis C virus (HCV). Patients who are seropositive because of hepatitis B virus vaccine are eligible.~* History of thromboembolic event within the last 3 months~* Known hypersensitivity to any component of Avastin

- Gender: FEMALE
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm 1 (Type: EXPERIMENTAL): At the expansion phase: Revlimid 20 mg (days 1-21), Doxil 30 mg/m2 on Day 1 and Avastin 15 mg/kg on Day 1, every 3 weeks. If this regimen is not cumulatively tolerable, Avastin will be administered every other course. Patients will be received up to 6 cycles or disease progression, followed by Revlimid maintenance at 25 mg PO q Day for 3 weeks every 4 weeks in patients with stable disease.

Based on this trial design, predict the completion outcome and termination type (if applicable).